MAP3K7 (Ab-187) Antibody

What is MAP3K7 (Ab-187) Antibody and what epitope does it recognize?

MAP3K7 (Ab-187) antibody is a polyclonal antibody raised in rabbits that specifically recognizes the threonine 187 phosphorylation site of the Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7) protein, also known as TGF-beta-activated kinase 1 (TAK1). The antibody is generated using a synthesized non-phosphopeptide derived from human MAP3K7 around the phosphorylation site of threonine 187 (H-M-T(p)-N-N) . This site-specific recognition enables researchers to monitor MAP3K7 activation status in various experimental contexts.

What species reactivity does MAP3K7 (Ab-187) Antibody demonstrate?

The MAP3K7 (Ab-187) antibody demonstrates cross-reactivity with multiple species, specifically:

• Human

• Mouse

• Rat

This cross-species reactivity makes it valuable for comparative studies across different model systems . The antibody has been affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen, ensuring high specificity for the target across these species .

What applications is the MAP3K7 (Ab-187) Antibody validated for?

The MAP3K7 (Ab-187) antibody has been validated for several research applications:

Some versions of the antibody may also be suitable for additional applications such as immunofluorescence (IF) and immunocytochemistry (ICC) .

How should MAP3K7 (Ab-187) Antibody be stored and handled to maintain its activity?

For optimal performance and longevity of the MAP3K7 (Ab-187) antibody, the following storage and handling conditions are recommended:

• For continuous use: Store undiluted antibody at 2-8°C for up to one week

• For long-term storage: Aliquot and store at -20°C

• Avoid storage in frost-free freezers as temperature cycling can degrade the antibody

• Avoid repeated freeze/thaw cycles

• Gently mix the antibody solution before use

• Consider centrifuging the vial prior to opening

• The antibody is typically supplied in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150mM NaCl, 0.02% sodium azide and 50% glycerol

Storage at -20°C typically maintains antibody stability for approximately 1 year .

What controls should be included when using MAP3K7 (Ab-187) Antibody for Western blotting?

When designing Western blot experiments with MAP3K7 (Ab-187) antibody, researchers should include the following controls:

• Positive control: Lysates from cells with known MAP3K7 expression and activation (such as HEK293T cells co-transfected with MAP3K7 and TAB1)

• Negative control: Lysates from cells with MAP3K7 knockout or knockdown

• Specificity control: Pre-incubation of the antibody with the immunizing peptide to confirm specificity

• Loading control: Detection of a housekeeping protein (e.g., GAPDH, β-actin) to ensure equal loading

• Phosphorylation status verification: Treatment with lambda phosphatase to confirm the specificity for the phosphorylated form

Research has shown that co-expression of MAP3K7 with TAB1 results in MAP3K7 autophosphorylation at Thr187, making this combination an excellent positive control system .

How can MAP3K7 (Ab-187) Antibody be used to distinguish between CSCF and FMD2 disease mechanisms?

MAP3K7 (Ab-187) antibody provides a powerful tool for investigating the molecular mechanisms underlying conditions associated with MAP3K7 variants. Research has demonstrated that MAP3K7 autophosphorylation at Thr187 can serve as a molecular fingerprint for distinguishing between:

• FMD2-related MAP3K7 variants: These typically show equal or increased levels of autophosphorylation at Thr187 compared to wild-type MAP3K7 when co-expressed with TAB1, suggesting a gain-of-function mechanism .

• CSCF-related MAP3K7 variants: Most of these variants exhibit significantly reduced pThr187 autophosphorylation levels compared to wild-type MAP3K7, indicating a loss-of-function mechanism .

This distinction is crucial for understanding the pathophysiology of these conditions and potentially developing targeted therapeutics. When designing experiments to investigate these variants, researchers should:

• Include both wild-type MAP3K7 and the variant of interest

• Co-express with TAB1 to stimulate autophosphorylation

• Use MAP3K7 (Ab-187) antibody to specifically detect phosphorylation at Thr187

• Examine both protein stability and phosphorylation status

What role does MAP3K7 Thr187 phosphorylation play in innate immune responses, and how can this antibody help investigate this function?

MAP3K7 (Thr187) phosphorylation has been identified as a key regulatory event in innate immune responses, particularly in kidney intercalated cells during urinary tract infections. Recent research has shown that:

• MAP3K7 mRNA expression increases in intercalated cells of both humans and mice following uropathogenic Escherichia coli (UPEC) exposure

• MAP3K7 protein expression, detected by immunofluorescence and confocal imaging, confirms this increased expression profile

• MAP3K7/TAK1 appears to be a key regulator of the intercalated cell antibacterial response

The MAP3K7 (Ab-187) antibody enables researchers to:

• Track changes in MAP3K7 Thr187 phosphorylation status during bacterial challenges

• Compare phosphorylation patterns between different cell types and organisms

• Investigate the temporal dynamics of MAP3K7 activation in response to pathogens

• Assess the effects of potential therapeutic interventions on this signaling pathway

This application highlights the antibody's utility in studying host-pathogen interactions and innate immunity mechanisms .

How can MAP3K7 (Ab-187) Antibody be used to investigate crosstalk between MAP3K7 and downstream signaling pathways?

MAP3K7 (Ab-187) antibody provides a valuable tool for investigating the complex network of signaling pathways downstream of MAP3K7 activation. Research has shown that MAP3K7 phosphorylation at Thr187 affects multiple pathways, including:

• NF-κB signaling pathway: MAP3K7 variants show differential effects on NF-κB phosphorylation levels, with most CSCF-related variants showing significantly reduced phosphorylated NF-κB levels .

• RAS-MAPK pathway: Contrary to expectations, most CSCF-related MAP3K7 variants result in reduced phospho-ERK levels compared to wild-type MAP3K7, distinguishing this condition from other syndromes with RAS-MAPK hyperactivation .

When designing experiments to investigate pathway crosstalk:

• Include both unstimulated and stimulated conditions (e.g., with cytokines, growth factors)

• Monitor multiple downstream targets simultaneously

• Consider temporal dynamics of activation

• Compare wild-type MAP3K7 with variants of interest

• Use the MAP3K7 (Ab-187) antibody to correlate Thr187 phosphorylation with downstream pathway activation

This approach allows researchers to build comprehensive models of how MAP3K7 integrates and regulates multiple signaling cascades .

What are common issues encountered when using MAP3K7 (Ab-187) Antibody in immunohistochemistry, and how can they be resolved?

When using MAP3K7 (Ab-187) antibody for immunohistochemistry, researchers may encounter several challenges:

• High background staining:

  • Potential cause: Insufficient blocking or antibody concentration too high

  • Solution: Optimize blocking conditions (increase blocking time/concentration) and titrate antibody dilution (try 1:100-1:300)

• Weak or absent signal:

  • Potential cause: Inadequate antigen retrieval or epitope masking

  • Solution: Ensure proper antigen retrieval by boiling tissue sections in sodium citrate buffer (pH 6.0) for 20 minutes

• Non-specific binding:

  • Potential cause: Cross-reactivity with similar epitopes

  • Solution: Pre-absorb the antibody with the immunizing peptide or use more stringent washing conditions

• Variable staining intensity:

  • Potential cause: Inconsistent fixation or processing

  • Solution: Standardize tissue handling protocols and include positive control tissues

• False negative results:

  • Potential cause: Loss of phospho-epitope during tissue processing

  • Solution: Use phosphatase inhibitors during sample preparation and minimize processing time

For optimal results, researchers should validate antibody performance on known positive control samples before proceeding with experimental tissues .

How can protein stability issues be addressed when studying MAP3K7 variants with the MAP3K7 (Ab-187) Antibody?

Research has shown that some MAP3K7 variants, particularly those associated with CSCF, demonstrate reduced protein stability. When using MAP3K7 (Ab-187) antibody to study these variants, consider the following approaches:

• Co-expression with stabilizing partners: Studies show that co-transfection with TAB1 can normalize expression levels of most CSCF-related MAP3K7 variants (except MAP3K7W241G). This approach helps distinguish between protein instability and intrinsic functional defects .

• Proteasome inhibition: Treatment with proteasome inhibitors (e.g., MG132) can help determine if reduced protein levels are due to enhanced degradation.

• Expression system optimization:

  • Use expression vectors with strong promoters

  • Optimize codon usage for the expression system

  • Consider using a tag that enhances stability

• Sample preparation optimization:

  • Include protease inhibitors in all buffers

  • Maintain samples at 4°C during processing

  • Process samples quickly to minimize degradation

  • Consider the addition of protein stabilizing agents

• Quantification approach:

  • Always normalize to appropriate loading controls

  • Consider calculating the ratio of phosphorylated to total MAP3K7 protein

These strategies enable more accurate assessment of MAP3K7 variant function by controlling for confounding effects of differential protein stability .

How can MAP3K7 (Ab-187) Antibody be used to investigate the role of MAP3K7 in developmental disorders?

MAP3K7 (Ab-187) antibody provides a valuable tool for investigating the molecular mechanisms underlying developmental disorders associated with MAP3K7 variants. Research has identified two distinct phenotypes:

• Frontometaphyseal dysplasia type 2 (FMD2): Associated with gain-of-function MAP3K7 variants that show equal or increased autophosphorylation at Thr187 .

• Cardiospondylocarpofacial syndrome (CSCF): Linked to loss-of-function MAP3K7 variants with reduced Thr187 phosphorylation .

To investigate these conditions using MAP3K7 (Ab-187) antibody, researchers can:

• Perform comparative analyses of MAP3K7 Thr187 phosphorylation in patient-derived samples

• Create cellular models expressing specific MAP3K7 variants

• Assess the impact of MAP3K7 variants on signaling pathway activation

• Correlate phosphorylation status with phenotypic outcomes in model systems

• Evaluate potential therapeutic approaches that modulate MAP3K7 signaling

This research approach helps elucidate genotype-phenotype correlations and may inform personalized treatment strategies for patients with these rare developmental disorders .

What insights can MAP3K7 (Ab-187) Antibody provide about MAP3K7's role in innate immunity and infection?

MAP3K7 (Ab-187) antibody enables detailed investigation of MAP3K7's role in immune responses, particularly in the context of urinary tract infections. Recent research has revealed:

• MAP3K7 mRNA expression increases in intercalated cells following exposure to uropathogenic Escherichia coli (UPEC)

• This response occurs in both human and mouse intercalated cells, suggesting an evolutionarily conserved defense mechanism

• MAP3K7/TAK1 appears to be a key regulator of antibacterial responses in kidney epithelial cells

To investigate these processes using MAP3K7 (Ab-187) antibody, researchers can:

• Compare phosphorylation patterns before and after pathogen exposure

• Analyze the temporal dynamics of MAP3K7 activation during infection

• Correlate Thr187 phosphorylation with downstream antimicrobial mechanisms

• Assess the effects of pathway inhibitors on host defense responses

• Investigate differences in MAP3K7 activation between susceptible and resistant individuals

These approaches can help identify potential targets for enhancing host defense mechanisms, particularly important in the context of increasing antibiotic resistance .

How can phospho-specific and total MAP3K7 antibodies be combined to comprehensively analyze MAP3K7 signaling dynamics?

A sophisticated experimental approach to MAP3K7 signaling involves the combined use of phospho-specific antibodies (like MAP3K7 Ab-187) and total MAP3K7 antibodies. This dual detection strategy provides several advantages:

• Normalization of phosphorylation signals:

  • Calculate the ratio of phosphorylated MAP3K7 to total MAP3K7

  • Control for variations in total protein expression

  • Provide more accurate quantification of activation status

• Temporal dynamics analysis:

  • Track both protein expression and phosphorylation over time

  • Distinguish between changes in activation versus changes in expression

  • Identify potential feedback mechanisms

• Spatial localization studies:

  • Use dual immunofluorescence to examine whether phosphorylated MAP3K7 localizes differently than total MAP3K7

  • Determine if phosphorylation affects protein trafficking

• Protein interaction analyses:

  • Combine with co-immunoprecipitation to identify phosphorylation-dependent protein interactions

  • Assess how phosphorylation status affects complex formation with regulators like TAB1

• Comprehensive pathway mapping:

  • Correlate MAP3K7 phosphorylation with activation of multiple downstream pathways

  • Generate integrated models of signaling networks

This comprehensive approach provides much richer information than measuring either parameter alone and helps resolve contradictory findings that may arise from examining only phosphorylation or only expression .

What considerations are important when designing experiments to compare wild-type and variant MAP3K7 function using the MAP3K7 (Ab-187) Antibody?

When comparing wild-type MAP3K7 to variants using MAP3K7 (Ab-187) antibody, researchers should consider several critical experimental design factors:

• Expression system selection:

  • Use systems that achieve comparable expression levels

  • Consider both transient and stable expression approaches

  • Evaluate endogenous versus overexpression systems

• Co-factor considerations:

  • Always include TAB1 co-expression conditions, as it significantly affects MAP3K7 stability and function

  • Consider testing with and without TAB1 to distinguish direct effects on MAP3K7 from effects on TAB1 interaction

• Stimulation conditions:

  • Include both basal and stimulated conditions (e.g., with cytokines like IL-1β or TNF-α)

  • Test multiple time points to capture temporal dynamics

• Comprehensive readouts:

  • Measure multiple parameters: protein levels, Thr187 phosphorylation, and downstream pathway activation

  • Include analysis of protein-protein interactions

  • Consider functional cellular assays relevant to MAP3K7 biology

• Analytical approach:

  • Normalize phosphorylation to total protein levels

  • Use appropriate statistical analysis for comparing multiple variants

  • Consider developing a comprehensive scoring system that integrates multiple parameters

This systematic approach enables more accurate characterization of MAP3K7 variants and their potential pathogenic mechanisms .